Your Article Summary
See Latest ArticlesPreparation and in-vitro bioactivity of a novel superantigen conjugate targeting bladder carcinoma
Journal of Pharmacy and Pharmacology, 06/29/09
Zhen C et al. - These findings indicate the conjugate of SEA protein and BDI-1 Fab fragment was prepared successfully and targeted bladder carcinoma in vitro.
Related Articles
Superficially invasive transitional cell carcinoma of the bladder associated with distant cutaneous metastases
Journal of Cutaneous Pathology, 11/18/09
Relevance Score: 68%
A disproportion of TH1/TH2 cytokines with predominance of TH2, in urothelial carcinoma of bladder
Urologic Oncology: Seminars and Original Investigations, 10/26/09
Relevance Score: 68%
Incidence analyses of bladder cancer in the Nile delta region of Egypt
Cancer Epidemiology, 10/20/09
Relevance Score: 68%
Dermatomyositis and small cell carcinoma of the bladder
Canadian Family Physician, 10/14/09
Relevance Score: 68%
Diagnosis and Treatment of Bladder Cancer
American Family Physician, 10/01/09
Relevance Score: 68%
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Pazopanib: therapeutic developments
Expert Opinion in Pharmacotherapy, 12/09/09
PD173074, a selective tyrosine kinase inhibitor of FGFR3, inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest
Journal of Pharmacology and Experimental Therapeutics, 12/09/09
Allos Therapeutics' FOLOTYN Shows Activity in a Dose Finding Phase 1 Study of Relapsed or Refractory Cutaneous T-Cell Lymphoma
Allos Therapeutics, 12/09/09